Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared a post on X:
“Insightful talk by Brian Rini, Uromigos on 1L mRCC! Ongoing debate TKI/IO vs IO/IO, sarcomatoid seems the best predictive biomarker, favoring IO; KIM1 seems highly prognostic in the adjuvant setting, is it also predictive?
OPTIC trial seems interesting!”
More posts featuring P.Grivas on OncoDaily.
